Genethon Presents Gene Therapy Advances at ESGCT Congress in Rome, 2024
- Genethon, based in France, is presenting groundbreaking gene therapy advancements at a significant conference.
- Twenty scientists from the laboratory will showcase their research and findings from clinical trials addressing various diseases.
- The participation highlights Genethon's leadership and contribution to improving patient outcomes through innovative therapies.
In October 2024, Genethon, a prominent French laboratory established by AFM-Telethon, is set to participate in the European Society of Gene & Cell Therapy's 31st Annual Congress taking place in Rome, Italy. The congress, scheduled from October 22 to 25, provides a platform for Genethon to showcase the latest developments in gene therapies targeting a variety of diseases, illustrating the evolution and potential of these innovative treatments in the medical field. Twenty scientists affiliated with Genethon will present their work, with topics ranging from the application of AAV vectors in gene therapy to CRISPR-Cas9 gene editing strategies. Key presentations will discuss the efficacy and safety of gene therapy products, offering valuable insights into the impact these therapies could have on rare diseases and conditions like Duchenne muscular dystrophy and glycogen storage diseases. The significance of this congress extends beyond scientific presentations; it emphasizes Genethon’s pioneering role in advancing gene therapy. With a total of thirteen products from Genethon's research and collaborations undergoing clinical trials, their contributions are critical in addressing unmet medical needs. By participating in this international forum, Genethon reinforces its commitment to improving patient lives through scientific breakthroughs, cementing its leadership position within the gene therapy landscape and potentially influencing future treatment paradigms.